🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 10 of 15

  1. glatiramer acetate with minocycline

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  2. laquinimod 0.3

    Teva Pharma GmbH

    Relapsing Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

  3. levodopa

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  4. methylprednisolone

    Teva Pharma GmbH

    Multiple Sclerosis (MS)

    phase 2 small molecule terminated

    1 trial

  5. mutual support group

    Hong Kong Baptist University

    Schizophrenia

    phase 2 other completed

    1 trial

  6. pallidotomy

    Ultragenyx UK Limited

    Parkinson Disease

    phase 2 other completed

    1 trial

  7. pioglitazone

    Takeda

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  8. sabirnetug

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  9. sarcosine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Schizophrenia

    phase 2 small molecule completed

    1 trial

  10. sodium oxybate

    Jazz Pharmaceuticals Ireland Limited

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  11. 300 mg [C14] CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  12. 50mg Ezogabine/retigabine

    GlaxoSmithKline

    Epilepsy

    phase 1 small molecule completed

    1 trial

  13. A Clinical Study to Assess the Safety, Tolerability of JNJ-63733657 and to evaluate how fast and to what extent JNJ-63733657 reaches the bloodstream and is absorbed, modified and removed from the body when administered as a Subcutaneous Infusion Using a Syringe Pump and as an Intravenous Infusion in Healthy Adult Participants

    Janssen-Cilag International N.V.

    Alzheimer's Disease (Healthy Participants)

    phase 1 other active

    1 trial

  14. A First-in-Human Study to Evaluate the Safety and Tolerability of ALN-APP in Patients with EOAD

    Alnylam Netherlands B.V.

    Early-onset Alzheimer's disease (EOAD)

    phase 1 other active

    1 trial

  15. A Multiple-Ascending-Dose Study of MK-1708 in Healthy Participants

    Merck Sharp and Dohme

    Amyotrophic lateral sclerosis and Alzheimer’s disease

    phase 1 other active

    1 trial

  16. A PET Study to Assess the Occupancy of M4 Muscarinic Acetylcholine Receptors by BMS-986521 in Healthy Adult Participants

    Bristol-Myers Squibb Australia Pty Ltd

    Neuropsychiatric indications and potentially other conditions

    phase 1 other active

    1 trial

  17. A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2)

    Celgene Europe Limited

    Myasthenia gravis (MG), Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis (RMS)

    phase 1 other active

    1 trial

  18. A Phase 1, Open-Label Study to Investigate the TARP-ɣ8 Receptor Occupancy of RAP-219 Using a TARP-γ8 PET Tracer in Healthy Adult Participants

    Rapport Therapeutics

    Epilepsy

    phase 1 other active

    1 trial

  19. A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial

  20. A Phase I, open-label, non-randomized study to evaluate the absorption, distribution, metabolism and excretion and pharmacokinetics of DLX313 (minzasolmin) following a single oral dose of [14C]DLX313 in healthy male participants

    Novartis Pharmaceuticals

    Parkinson’s Disease

    phase 1 other active

    1 trial

  21. A Randomized, Multiple-Dose, Open-Label, Parallel-Group Study to Evaluate the Pharmacokinetic Profiles of LY03010 and the Relative Bioavailability at Steady-State of LY03010 versus XEPLION® in Patients with Schizophrenia

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  22. A SINGLE-ARM, OPEN-LABEL, PHASE I STUDY TO DETERMINE THE SAFETY, TOLERABILITY, AND PRELIMINARY EFFICACY OF OBE-CEL IN PARTICIPANTS WITH REFRACTORY PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS

    Autolus GmbH

    Refractory Progressive Multiple Sclerosis

    phase 1 other active

    1 trial

  23. A Study to Assess Distribution, Binding, and Retention of the Monoclonal Antibody Trontinemab in the Brain of Healthy Participants and Patients with Alzheimer’s Disease

    Hoffmann-La Roche

    Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  24. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease

    Denali Therapeutics

    Early Alzheimer's Disease

    phase 1 other active

    1 trial

  25. A Study to Investigate Single Ascending Doses of Ocrelizumab for Safety and Side Effects, How The Body Handles It Over A Period of Time, How The Body Notices and Reacts To It, And Its Effect On The Body When Given As A Subcutaneous Injection In Patients With Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  26. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  27. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of RO7121932 following Intravenous and Subcutaneous Administration in Participants with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial

  28. A clinical trial to learn how an investigational drug (MP-101) affects on the laboratory signs of the disease when given to Amyotrophic Lateral Sclerosis (ALS) and Alzheimer’s Disease (AD) patients

    Lacuna Pharma Pty Ltd

    Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s Disease (AD)

    phase 1 other active

    1 trial

  29. A positron emission tomography study of synaptic nerve cells proteins alpha-7 nicotinic acetylcholine receptors in brain of healthy volunteers and patients with mild cognitive impairment and Alzheimer´s disease.

    The George Institute

    Alzheimer´s disease

    phase 1 other active

    1 trial

  30. A randomised, double-blind, placebo-controlled phase Ib trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple doses of ACD856 in healthy participants

    Lacuna Pharma Pty Ltd

    Depression, Cognitive dysfunction, Alzheimer’s disease

    phase 1 other active

    1 trial

  31. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Hoffmann-La Roche

    Healthy males volunteers

    phase 1 other active

    1 trial

  32. A study to find out how healthy people tolerate a new drug called S221237.

    The George Institute

    Parkinson disease (PD)

    phase 1 other active

    1 trial

  33. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

    Hoffmann-La Roche

    Parkinson’s Disease

    phase 1 other active

    1 trial

  34. ACTOS (Pioglitazone)

    Takeda

    Multiple Sclerosis, Relapsing-Remitting

    phase 1 small molecule completed

    1 trial

  35. ACU193

    Acumen Pharmaceuticals

    Alzheimer Disease

    phase 1 small molecule completed

    1 trial

  36. ALN-5288

    Alnylam Netherlands B.V.

    Alzheimer's Disease

    phase 1 small molecule active

    1 trial

  37. ALN-APP

    Alnylam Netherlands B.V.

    Early-Onset Alzheimer Disease

    phase 1 small molecule active

    1 trial

  38. ALN-SNCA

    Regeneron UK Limited

    Parkinsons Disease

    phase 1 small molecule active

    1 trial

  39. APX005M treatment for recurrent or refractory primary malignant CNS tumor patients

    Pyxis Oncology

    Glioblastoma Multiforme

    phase 1 mab active

    1 trial

  40. An Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants with Schizophrenia

    Lacuna Pharma Pty Ltd

    Schizophrenia

    phase 1 other active

    1 trial

  41. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.

    Lacuna Pharma Pty Ltd

    Bipolar disorder, Epilepsy

    phase 1 other active

    1 trial

  42. An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Brivaracetam Tablets Ph. Eur. 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Briviact (brivaracetam) 100 mg film-coated tablets, Marketing Authorisation Holder: UCB Pharma S.A., Allée de la Recherche 60, B-1070 Bruxelles, Belgium; Manufactured by UCB Pharma S.A., Chemin du Foriest, B-1420 Braine-l’Alleud, Belgium, in healthy adult, human subjects und

    Lacuna Pharma Pty Ltd

    Epilepsy

    phase 1 other active

    1 trial

  43. BIIB094

    IONIS PHARMACEUTICALS INC

    Parkinson's Disease

    phase 1 small molecule completed

    1 trial

  44. BIS-001 ER

    SUPERNUS PHARMACEUTICALS, INC.

    Epilepsy, Complex Partial

    phase 1 small molecule completed

    1 trial

  45. BXCL501 80 Micrograms

    BioXcel Therapeutics

    Schizophrenia

    phase 1 small molecule active

    1 trial

  46. Bioequivalence of Cladribine 10 mg from two different products

    Lacuna Pharma Pty Ltd

    No therapeutic indication in the current trial with healthy volunteers. The intended indication is for treatment of adult patients with highly active relapsing multiple sclerosis (MS).

    phase 1 other active

    1 trial

  47. Bioequivalence study 1 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion Laboratories Pty.

    Parkinson disease

    phase 1 other active

    1 trial

  48. Bioequivalence study 2 to compare pharmacokinetics of Parkinson´s disease drugs in healthy volunteers

    Orion Laboratories Pty.

    Parkinson desease

    phase 1 other active

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.